Strata Critical Medical, Inc. (SRTA) is a small-cap healthcare company that provides time-critical logistics and medical services, including organ transport and transplant clinical services. It was formerly known as Blade Air Mobility and adopted its current name and ticker in August 2025 after selling its passenger business to Joby Aviation.
Four sell-side analysts currently carry price targets on the stock, and the average analyst price target works out to about $9.56, which I have rounded to a central target of $9.50. The individual targets span a wide range from $8.00 to $12.75. Coverage is uniformly bullish: Craig-Hallum and B. Riley both initiated Buy ratings with $8.00 targets in March 2026, Lake Street has maintained a Buy rating (with its target in the $8.00-to-$9.50 area), and Ladenburg Thalmann carries the highest target, near $12.75, after raising its objective several times through 2026.
The reasoning behind these targets is consistent rather than contested. Analysts focus on the company's leading position in organ-transplant logistics, the $124 million acquisition of Keystone Perfusion Services as a use of its sizable cash balance, and management's 2026 revenue guidance of $255 million to $270 million. The divergence between the low and high targets largely reflects different assumptions about margin expansion, integration execution, and the pace at which the business reaches sustained profitability.
Shares trade near $4.72, giving the company a market capitalization of roughly $418 million. From that level, reaching the $9.50 central target would require an increase of approximately 100%, which is a very large move for a 12-month research horizon.
The path toward the target would need to be built on fundamentals rather than valuation alone. The company is growing revenue quickly and reaffirmed its fiscal 2026 guidance, but it remains unprofitable, with negative EPS (earnings per share) over the trailing twelve months. Because the stock has no meaningful P/E (price-to-earnings) anchor today, investor support depends on demonstrating that the combined logistics and clinical businesses can scale margins and turn cash-flow positive, which is precisely what the higher analyst targets assume.
Over the past year, the shares have traded in a broad range from roughly $2.55 to about $6.50. The $6.50 area represents a meaningful resistance level, as it marks the prior 52-week high and sits roughly 38% above the current price. Below, the $4.00 level has acted as a support zone. Reaching $9.50 would require not only breaking above the prior high near $6.50 but extending well beyond it, meaning the stock would need to establish new all-time-high territory on sustained buying interest.
Analyst price targets generally reflect a roughly 12-month research horizon, though firms may update them at any time. Investors should monitor quarterly results and the November earnings report, progress on integrating Keystone, updates to full-year guidance, and any analyst target revisions following earnings. For a stock valued primarily on future growth, the most important signals are revenue momentum, gross-margin trends, and the path toward profitability rather than short-term price movement.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. If you want to streamline your daily market review, exploring the AI Daily Buy/Sell Signals can help you keep pace with fast-changing conditions.
The question of whether SRTA can reach $9.50 is best understood as a test of execution rather than valuation. The central target is the rounded mean of four analyst targets that average about $9.56, within a wide $8.00-to-$12.75 range, and it implies roughly a 100% move from the current price near $4.72. The bull case rests on organ-transplant logistics demand, the Keystone acquisition, and strong revenue guidance, while the bear case centers on continued losses, a rich revenue multiple, and integration risk. Analyst agreement on the "Strong Buy" rating is broad, but the wide spread between the low and high targets signals genuine uncertainty about how quickly margins will improve. Investors should focus next on earnings, guidance, margin progress, and any analyst revisions rather than treating the average target as a promise.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, SRTA has been loosely correlated with JOBY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if SRTA jumps, then JOBY could also see price increases.
| Ticker / NAME | Correlation To SRTA | 1D Price Change % | ||
|---|---|---|---|---|
| SRTA | 100% | -0.50% | ||
| JOBY - SRTA | 57% Loosely correlated | -4.21% | ||
| UP - SRTA | 36% Loosely correlated | -10.87% | ||
| AIRS - SRTA | 25% Poorly correlated | +14.11% | ||
| JYNT - SRTA | 24% Poorly correlated | +2.71% | ||
| STLN - SRTA | 24% Poorly correlated | +8.50% | ||
More | ||||
| Ticker / NAME | Correlation To SRTA | 1D Price Change % |
|---|---|---|
| SRTA | 100% | -0.50% |
| Hospital/Nursing Management industry (48 stocks) | 5% Poorly correlated | -1.98% |
| Health Services industry (239 stocks) | -0% Poorly correlated | -1.13% |